The Atractiv project: Improvement of cardiovascular preventiv in primary care in the Czech Republic;Projekt atractiv: Zlepšení kardiovaskulární prevence v podmínkách primární péče v České republice

Vnitrni Lekarstvi

Volumn 54, Issue 12, 2008, Pages 1131-1139

  Vrablík, Michal ^a   Freiberger, T ^b   Lanska V ^c   Ceska R ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Geneticka Laborator Centra Kardiovaskularni a Transplantacni Chirurgie Brno

^c Jisteni Jakosti a Controllingu Institutu Klinicke a Experimentalni Medicny Praha ^*

Author keywords

Antihypertensive drugs; Arterial hypertension; Cardiovascular risk; Dyslipidemia; Statins

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PERINDOPRIL; RAMIPRIL; TRIACYLGLYCEROL;

AGED; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CZECH REPUBLIC; DIET RESTRICTION; DRUG TOLERABILITY; DYSLIPIDEMIA; EVIDENCE BASED PRACTICE; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY FUNCTION TEST; LABORATORY TEST; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIMARY MEDICAL CARE; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; CARDIOVASCULAR DISEASE; HEALTH CARE; MIDDLE AGED; PRIMARY HEALTH CARE; RISK FACTOR;

CARDIOVASCULAR DISEASES; COMPREHENSIVE HEALTH CARE; CZECH REPUBLIC; DYSLIPIDEMIAS; FEMALE; HUMANS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; RISK FACTORS;

EID: 57849112371     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Euroaspire III. Euro Heart Survey, Wien, September 2007, www.escardio.org.
2. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 2005; 46: 1225-1228.
3. Zdravotnická ročenka ČR 2006. Ústav zdravotnických informací. www.uzis.cz.
4. Gaede P, Vendel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
5. Vaverková H, Soška V, Rosolová H et al. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracované výborem České společnosti pro aterosklerózu. Vnitř Lék 2007; 53: 181-197.
6. Widimský J jr., Cífková R, Špinar J et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2007. Vnitř Lék 2008; 54: 101-118.
7. Graham I, Atar D, Borch-Johsen K et al. European guidelines on cardiovascular disease prvevention in clinical practice: executive summary. Eur Hear J 2007; 28: 2375-2434.
8. Sever PS, Dahlöf B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158.
9. Conroy R, Pyorala K, Fitzgerald A et al. Prediction of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003.
10. Friedewald WT, Levy RJ, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-509.
11. Alexander CM, Landsman PB, Teutsch SM (NHANES III) et al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 and older. Diabetes 2003; 52: 1210-1214.
12. Widimský J jr. Výsledky sledování rizikových faktorů a klinických účinků rilmenidinu u nemocných s arteriální hypertenzí. Farmakoterapie 2008; 3: 325-328.
13. Souček M, Widimský J sr., Lánská V. Control of hypertension in patients with hypertension, diabetes, and impaired fasting glucose by Czech primary care physicians. Kidney Blood Press Res 2006; 29: 366-372.
14. Škrha J. Diabetes mellitus 2002 v České republice - Epidemiologická studie. DMEV 2005; 8: 5-12.
15. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.
16. Cannon CP, Braunwald E, McCabe CH et al. Comparison of intensit and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
17. Pedersen TR, Faergeman O, Kastelein JJP et al. High-dose atorvastatin vs usual-dose simvastatin for secondary preventiv after myocardial infarction: the IDEAL study: a randomised controlled study. JAMA 2005; 294: 2437-2445.
18. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotenzin-converting enzyme inhibitor or calcium-channel rocker vs. diuretic. JAMA 2002; 288: 2981-2997.
19. Patel A, Mac Mahon S, Chalmers J. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomoes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
20. Mancia G, De Backer G, Dominiczak A et al. Management of Arterial Hypertension of the European Society of Hypertension. J Hypertens 2007; 25: 1105-1187.
21. Kjeldsen SE, Jamerson KA, Bakris GL et al. Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension investigators. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press 2008; 17: 7-17.
22. Cockroft JR. Angiotensin converting enzyme inhibition in hypertension: focus on perindopril. Am J Cardiovasc Drugs 2007; 7: 303-317.
23. Mogensen CE. New concepts in blood pressure-lowering management in diabetic patients: the case for early ACE inhibitor combination therapy with diuretics. J Hum Hypertens 2001; 9 (Suppl 1): S15-S20.
24. de Koning L, Merchant AT, Pogue J et al. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J 2007; 28: 850-856.
25. Rydén L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007; 28: 88-136.
26. Perkins JM, Davis SN. The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control. Curr Opin Endocrinol Diabetes Obes 2008; 15: 147-152.